Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)

Main Article Content

Christos C Zouboulis
Martin M Okun
Robert Gniadecki
Peter A Foley
Charles Lynde
Jamie Weisman
Piyalal Karunaratne
David A Williams

Keywords

adalimumab, hidradenitis suppurativa, therapeutics

Abstract

Abstract Not Available

Disclosures: Study supported by AbbVie.